Ludwig Institute for Cancer Research Limited

Massachusetts Institute of Technology

Commonwealth Scientific and Industrial Research Organisation

University of California

Abbott Laboratories Corporation

Beijing University of Technology

Terrance Grant Johns

Lloyd J Old

Andrew Ewart Scott

Antony Wilks Burgess

K Dane Wittrup

Webster K Cavenee

Timothy Edward Adams

Andrew Mark Scott

Peter Anthony Hoyne

Ginger Chao

Gerd J Ritter

Elisabeth Stockert

Con Panousis

Edouard Collins Nice

Christoph Renner

Achim Jungbluth

Elizabeth Stockert

Anne Murray

George Mark

Frank Furnari

Ermanno Gherardi

Peter Collins

Huei-Jen Su Huang

Veronika M Rayzman

Anthony Wilks Burgess

Andrew Scott

Huei-Jen Huang

Llyod J Old

Elisabeth (deceased) Stockert

The present invention relates to antibodies, particularly antibody 175, and fragments thereof or antibodies derived therefrom, which bind to the EGF receptor, particularly to amplified or overexpressed epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. These antibodies are useful in the diagnosis and treatment of cancer. Recombinant or hybrid antibodies having the variable region heavy or light chain sequence(s) of antibody 175 are also provided. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof

The present invention relates to antibodies that specifically bind to unprocessed c-Met present on the surface of tumor cells. These antibodies are useful in the diagnosis and treatment of cancer or as agents for delivering moieties to cancer cells. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents.

Antibodies directed to the receptor tyrosine kinase c-Met

The present invention relates to the treatment of EGFR-mediated disease, particularly cancer by inhibiting or blocking EGFR and src in combination or simultaneously. The invention relates to treatment, prevention, or modulation of cancer, particularly EGFR-mediated disease, with one or more EGFR modulator and src inhibitor in combination. The invention further relates to the treatment of cancer with anti-EGFR antibodies and src inhibitors. Methods and compositions for treatment of cancer with the antibody anti-EGFR mAb806 in combination or series with a src inhibitor or src inhibitors are described.

Treatment method using EGFR antibodies and SRC inhibitors and related formulations

The present invention relates generally to growth factor receptor epitope peptides, particularly EGF family receptor epitope peptides. The invention also relates to the use of the receptor peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against the receptor peptides. Methods for generating an immune response and for treatment of tumors and cancer are also provided.

Antibodies to EGF receptor epitope peptides and uses thereof

Antibodies to EGF receptor epitope peptides

The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.

Specific binding proteins and uses thereof

Growing community of inventors

Melbourne, Australia

Terrance Grant Johns